NCT05745610

Shen Hai Long Capsule for Male Asthenospermia

An Clinical Trial on the Efficacy and Safety of Shen Hai Long Capsule in the Treatment of Male Asthenospermia

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Zhongnan Hospital · Academic / Other
• Sex: Male
• Age: 22 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy and safety of Shen Hai Long Capsule in the treatment of mild to moderate asthenospermia in men.

Detailed description

To evaluate the efficacy and safety of Shen Hai Long Capsule in the treatment of mild to moderate asthenospermia in men: 1) Efficacy index (1) Main efficacy indexes Forward motile sperm ratio (PR) (2) Secondary efficacy indexes 1. Sperm survival rate; 2. Sperm concentration; 3. Normal morphology rate of sperm; 4. Seminal malondialdehyde (MDA) 5. Seminal superoxide dismutase (SOD) 2) Safety indicators (1) Vital signs; (2) liver and kidney function; (3) blood routine; (4) electrocardiogram; (5) Adverse events.

Conditions

• Efficacy and Safety of Shen Hai Long Capsule for Mild to Moderate Asthenospermia in Men

Interventions

Type	Name	Description
DRUG	Shen Hai Long Capsule	3 times/day (9 capsules/day) for 12 weeks
DRUG	Sheng Jing Capsule	3 times/day (12 capsules/day) for 12 weeks

Timeline

• Start date: 2023-02-15
• Primary completion: 2024-06-30
• Completion: 2024-12-31
• First posted: 2023-02-27
• Last updated: 2023-02-27

Locations

1 site across 1 country: China